MANISH DESAI to Outpatients
This is a "connection" page, showing publications MANISH DESAI has written about Outpatients.
Connection Strength
0.341
-
The COVID-19 Outpatient Pragmatic Platform Study (COPPS): Study design of a multi-center pragmatic platform trial. Contemp Clin Trials. 2021 09; 108:106509.
Score: 0.165
-
Evaluation of Acebilustat, a Selective Inhibitor of Leukotriene B4 Biosynthesis, for Treatment of Outpatients With Mild-Moderate Coronavirus Disease 2019: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial. Clin Infect Dis. 2023 07 26; 77(2):186-193.
Score: 0.048
-
Favipiravir for Treatment of Outpatients With Asymptomatic or Uncomplicated Coronavirus Disease 2019: A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial. Clin Infect Dis. 2022 11 30; 75(11):1883-1892.
Score: 0.045
-
Inflammatory but not respiratory symptoms are associated with ongoing upper airway viral shedding in outpatients with uncomplicated COVID-19. Diagn Microbiol Infect Dis. 2022 Mar; 102(3):115612.
Score: 0.042
-
Peginterferon Lambda-1a for treatment of outpatients with uncomplicated COVID-19: a randomized placebo-controlled trial. Nat Commun. 2021 03 30; 12(1):1967.
Score: 0.041